Atlas Trials

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

Clinical trial NCT07299890 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07299890
Sponsor
Anhui Provincial Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2025-12-20
Primary completion
2027-11-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.